Arrow International's R&D capabilities and complementary business model enticed Teleflex to buy the critical care device maker for $2 billion as part of an ongoing transformation of its device business, the firms said July 23 (see chart: "1Teleflex-Arrow Deal Basics")
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Already a subscriber?
In this week's Digital Health Roundup, Medtech Insight's team discusses progress on autonomous surgery, Medtronic's new partnership with IRCAD, FDA cybersecurity news, and C-suite interviews with OpenWater, Flow Neuroscience and EnsoData.
A recent FDA warning letter claims a Boston firm that specializes in wearable technology marketed a blood pressure device without agency approval. The company rejects the assertion and says the agency is out of step with federal law.
US Medicare has proposed national coverage of renal denervation for patients with uncontrolled hypertension. The treatment is seeing other advances as well, with Medtronic piloting a longer catheter and a multi-organ approach and a blood test to identify the best candidates fresh on the
